Skip to content
    RTW Investments logo

    RTW Investments

    New York, New York, United StatesFounded 2010

    RTW Investments is a life sciences investment and innovation firm headquartered in New York, investing in biotech and medtech across the full lifecycle from company creation to venture capital, alternative financing, and public companies.

    62% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 10 prior). Average disclosed round size is $134.1M (across 38 rounds with reported amounts).

    Find people at RTW Investments on Goldilocks AI

    Portfolio

    34

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    Sabera Loughran

    Sabera Loughran

    Partner Emeritus, Founding COO and CFO

    Danielle Petras

    Danielle Petras

    Executive Assistant to the Managing Partner

    Roderick Wong, MD

    Roderick Wong, MD

    Managing Partner, Chief Investment Officer

    Dan Glynn

    Dan Glynn

    Managing Director, Private Wealth

    John Wasilewski

    John Wasilewski

    Managing Director, Business Development

    Lauren Cuje

    Lauren Cuje

    Managing Director, New Ventures

    Matthew Bieret, CPA

    Matthew Bieret, CPA

    Managing Director, Finance

    Mike Christman

    Mike Christman

    Managing Director, Operations

    Paul Lu, PhD

    Paul Lu, PhD

    Managing Director, Head of Corporate Development

    Piratip Pratumsuwan

    Piratip Pratumsuwan

    Managing Director, Research Analyst

    Scott Band, CPA

    Scott Band, CPA

    Managing Director, Tax

    Sean Haggerty

    Sean Haggerty

    Managing Director

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    42 investments
    CompanyRoundAmountDate
    Prolium Bioscience, Inc. logoProlium Bioscience, Inc.Series A$50MMar 2026
    CCorxel Pharmaceuticals LimitedSeries D$287MJan 2026
    Artiva Biotherapeutics logoArtiva BiotherapeuticsSeries B$120MJan 2026
    Prolium Bioscience, Inc. logoProlium Bioscience, Inc.Series A$50MJan 2026
    Crescent Biopharma logoCrescent BiopharmaGrowth$200MJun 2025
    Umoja logoUmojaSeries C$100MJan 2025
    Windward Bio logoWindward BioSeries A$200MJan 2025
    Numab logoNumabSeries C$55MJan 2025
    RAPT Therapeutics logoRAPT TherapeuticsSeries D$150MDec 2024
    Ottimo Pharma logoOttimo PharmaSeries A$140MDec 2024
    Evommune logoEvommuneSeries C$115MOct 2024
    Kailera Therapeutics logoKailera TherapeuticsSeries A—Oct 2024
    Aktis Oncology logoAktis OncologySeries B$175MSep 2024
    Ventyx Biosciences logoVentyx BiosciencesSeries A$27MSep 2024
    Lycia Therapeutics logoLycia TherapeuticsSeries C$106.6MMay 2024
    Kailera Therapeutics logoKailera TherapeuticsUnknown—Oct 2023
    CARGO Therapeutics logoCARGO TherapeuticsSeries A$200MJan 2023
    Apogee logoApogeeSeries B$149MDec 2022
    Mineralys Therapeutics logoMineralys TherapeuticsSeries B$118MJun 2022
    PPrometheus BiosciencesUnknown$500MJan 2022
    Apogee logoApogeeSeries B$149MJan 2022
    Lycia Therapeutics logoLycia TherapeuticsSeries B$70MSep 2021
    Ventyx Biosciences logoVentyx BiosciencesSeries B$51MSep 2021
    Artios logoArtiosSeries C$153MJul 2021
    AArtios Pharma LimitedSeries C$153MJul 2021
    Page 1 of 2

    Top Co-Investors

    Last updated: 7 October 2026